Gilead Sciences, Inc. (GILD) vs GSK PLC Sponsored ADR (GSK)
- Gilead Sciences, Inc. GILD 156.19 −0.75%
- GSK PLC Sponsored ADR GSK 49.55 +1.08%
Gilead Sciences, Inc. and GSK PLC Sponsored ADR are both Drug Manufacturers General companies. Gilead Sciences, Inc. is the larger, with a market value of $195.1B against $98.2B — 2.0× the size. Gilead Sciences, Inc. has negative trailing earnings, so its P/E is not meaningful; GSK PLC Sponsored ADR trades at 15.4×. GSK PLC Sponsored ADR grew revenue faster over the last twelve months: 8.72% against 5.52%. GSK PLC Sponsored ADR has the higher net margin (14.6% vs −10.6%) and the higher return on invested capital (12.6% vs −4.48%). Both pay a dividend; GSK PLC Sponsored ADR yields more (3.67% vs 2.08%). Across the 22 metrics below, GSK PLC Sponsored ADR leads on 15 and Gilead Sciences, Inc. on 7.
Valuation
Profitability
| Metric | GILD | GSK | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 79.59% | 72.75% | 72.77% |
| Operating margin | (8.20%) | 19.55% | 18.77% |
| Net margin | (10.64%) | 14.58% | 8.27% |
| Free cash flow margin | 42.50% | 17.18% | 17.18% |
| Return on equity | (20.68%) | 30.74% | 5.87% |
| Return on assets | (6.17%) | 8.01% | 2.57% |
| Return on invested capital | (4.48%) | 12.58% | 6.11% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack